Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into patient responses to CAR-T therapy, and further discusses factors that may influence these responses, including high-risk features and previous exposure to anti-BCMA therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.